ORION CORPORATION         PRESS RELEASE         28 June 2022 at 11.30 EEST
        

Orion publishes Half-Year Financial Report for January–June 2022 on Friday 15 July 2022

Orion will publish Half-Year Financial Report for January–June 2022 on Friday, 15 July 2022 at approximately 12.00 noon EEST. The release and related presentation material will be available on the company’s website at www.orion.fi/en/investors after publishing.

Webcast and conference call

A webcast and a conference call for analysts, investors and media will be held on Friday, 15 July 2022 at 13.30 EEST. The event will be held only online and by conference call.

A link to the live webcast will be available on Orion's website at www.orion.fi/en/investors. A recording of the event will be available on the website later the same day.

To participate in the conference call, please dial:

Finland: +358 9 817 103 10
Sweden: +46 8 566 426 51
United Kingdom: +44 333 300 0804
United States: +1 631 913 1422

PIN: 29705083#

Silent period

The silent period preceding the publication is ongoing and continues until the disclosure.

                                                
Contact person:
Tuukka Hirvonen, Investor Relations, Orion Corporation
tel. +358 10 426 2721

Publisher:
Orion Corporation
Communications
Orionintie 1A, FI-02200 Espoo, Finland
www.orion.fi

Orion is a globally operating Finnish pharmaceutical company – a builder of well-being. Orion develops, manufactures and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients. The company is continuously developing new drugs and treatment methods. The core therapy areas of Orion’s pharmaceutical R&D are oncology and pain. Orion’s net sales in 2021 amounted to EUR 1,041 million and the company had about 3,350 employees at the end of the year. Orion’s A and B shares are listed on Nasdaq Helsinki.